Back to discover
§ The cross-read
MRK vs REGN
MRK's Section-2 severe Keytruda Cliff risk is the dominant variable in any cross-read.
Fair-value ladder
Fair-value ladder unavailable — one or both tickers have no published mid fair value.
Aligned scorecards
MRKREGN
| MRKMerck & Co. Inc. | REGNRegeneron Pharmaceuticals Inc. | |
|---|---|---|
| Trend | - | - |
| Price | - | - |
| Fair value | - | - |
| FV range | - | - |
| Upside | - | - |
| Rating | Giữ | Giữ |
| Confidence | - | - |
| Moat | - | - |
| Archetype | - | - |
| Sector | Health Care | Health Care |
| Analyzed | - | - |
9-category scorecards
MRK
Merck & Co. Inc.
Valuation
5.0/10
0.11x
Management
5.9/10
0.11x
Balance Sheet
5.0/10
0.11x
Profitability
6.5/10
0.11x
Revenue Growth
4.5/10
0.11x
Risk Assessment
7.0/10
0.11x
Competitive Moat
9.0/10
0.11x
Earnings Quality
4.5/10
0.11x
Capital Efficiency
6.0/10
0.11x
Weighted Overall
5.9/10
REGN
Regeneron Pharmaceuticals Inc.
Valuation
5.0/10
0.11x
Management
6.9/10
0.11x
Balance Sheet
8.5/10
0.11x
Profitability
6.5/10
0.11x
Revenue Growth
7.5/10
0.11x
Risk Assessment
9.0/10
0.11x
Competitive Moat
9.0/10
0.11x
Earnings Quality
6.0/10
0.11x
Capital Efficiency
6.5/10
0.11x
Weighted Overall
7.2/10